In a report published Tuesday, Deutsche Bank analyst Alethia Young initiated coverage on Verastem VSTM with a Buy rating and $14.00 price target.
In the report, Deutsche Bank noted, “Verastem's lead asset is VS-6063 for the treatment of mesothelioma currently in pivotal studies. We see VSTM as a platform cancer company based on its robust scientific grounding around cancer stem cells. Pipeline opportunities are a free call option, in our view, while mesothelioma market size & potential clinical success are unappreciated. VSTM's market cap is ~$200M and shares are trading near cash of ~$4.5/sh. Shares are also trading at 52-week low although clinical progress has been made in 12 months.”
Verastem closed on Monday at $8.05.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in